Clinical Trial Update: A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update describes fedratinib in Japanese patients with DIPSS-intermediate/high-risk primary myelofibrosis, post-polycythemia vera myel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Post-essential Thrombocythemia Myelofibrosis
• Post-polycythemia Vera Myelofibrosis

Drugs mentioned

• INREBIC (fedratinib hydrochloride)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Primary Myelofibrosis | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING